2[2]Ottesen Jl,Nilsson P,Jami J,et al.The potential immunog enicity of human insulin and insulin analogues evaluated in a transgenic mouse model.Diabetologia,1994,37:1178-1185
3[3]Lindholm A,McEwen J,Riss AP.Improved postprandial glycaemic control with insulin aspart-arandomized double-blinde cross over trial in type 1diabetes mellitus.Diabetes Care,1999,22:801-805
4[4]Rosenfalck A,Thorsby P,Rjems L,et al.Improved postprandial glycaemic controls with insulin Aspart in type 2 diabetic patients treated with insulin.Acta Diabetologia,2000,37:41-46
5[5]Jacobsen LV,Sogard B,Riis A.Pharmacokinetics and pharmacody namics of a premixed formulation of soluble and protamine retarded insulin aspart.Eur Clin Pharmacol,2000,56:399-403
6[6]Mcsorleg PT,Bell PM,Jacobsen LV,et al.Twice-dailg biphasic in sulin aspart 30 versus biphasic human insulin 30:a double-blind cross over study in adults with type 2 diabetes mellitus.Clin Ther,2002,24(4):530-539
7[7]Boehm BO,Vaz JA,Brondsted L,et al.Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes.Eur Inter Med,2004(15):496-502
